We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

77 hedge funds and large institutions have $102M invested in Karyopharm Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

85% more call options, than puts

Call options by funds: $31.3M | Put options by funds: $16.9M

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

47% more capital invested

Capital invested by funds: $69.6M → $102M (+$32.6M)

43.31% more ownership

Funds ownership: 55.52% → 98.83% (+43%)

12% more funds holding

Funds holding: 69 → 77 (+8)

Holders
77
Holders Change
+8
Holders Change %
+11.59%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
32
Reduced
9
Closed
15
Calls
$31.3M
Puts
$16.9M
Net Calls
+$14.4M
Net Calls Change
+$14.3M

Top Buyers

1
CC
Commodore Capital
New York
+$14.9M
2
RCM
RA Capital Management
Massachusetts
+$14.6M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.6M
4
Goldman Sachs
Goldman Sachs
New York
+$7.22M
5
APM
Avidity Partners Management
Texas
+$6.04M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.84M
2
AAA
Affinity Asset Advisors
New York
-$2.97M
3
B
Braidwell
Connecticut
-$2.23M
4
EAM
Exome Asset Management
New York
-$2.18M
5
Ameriprise
Ameriprise
Minnesota
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
26
XTX Topco
Cayman Islands
$916K +$1.16M +152,539 +1,281%
Two Sigma Investments
27
Two Sigma Investments
New York
$842K +$18.6K +2,439 +2%
ACM
28
ADAR1 Capital Management
Texas
$762K +$661K +86,736 +173%
Marshall Wace
29
Marshall Wace
United Kingdom
$715K – – –
VFT
30
Vanguard Fiduciary Trust
Pennsylvania
$640K +$876K +114,934 New
EGM
31
Engineers Gate Manager
New York
$626K +$857K +112,432 New
Jane Street
32
Jane Street
New York
$590K +$536K +70,368 +198%
Renaissance Technologies
33
Renaissance Technologies
New York
$587K +$347K +45,500 +76%
CWG
34
C WorldWide Group
Denmark
$557K – – –
BC
35
Birchview Capital
Vermont
$468K +$640K +83,952 New
State Street
36
State Street
Massachusetts
$450K +$166K +21,800 +37%
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$440K +$167K +21,869 +38%
BCM
38
Bridgeway Capital Management
Texas
$400K +$45.7K +6,000 +9%
Balyasny Asset Management
39
Balyasny Asset Management
Illinois
$394K +$539K +70,748 New
SAM
40
Silverback Asset Management
North Carolina
$362K +$191K +25,000 +63%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$336K +$18.3K +2,399 +4%
TAM
42
TFG Asset Management
Cayman Islands
$295K +$404K +52,984 New
DCM
43
DAFNA Capital Management
California
$255K -$39.6K -5,200 -10%
Northern Trust
44
Northern Trust
Illinois
$215K +$72.7K +9,533 +33%
ZP
45
Zimmer Partners
New York
$209K +$286K +37,500 New
CC
46
Centiva Capital
New York
$168K +$230K +30,210 New
CUAMC
47
China Universal Asset Management Company
China
$167K +$229K +30,000 New
Baird Financial Group
48
Baird Financial Group
Wisconsin
$166K +$13.7K +1,798 +6%
SPS
49
Susquehanna Portfolio Strategies
Pennsylvania
$139K +$191K +25,021 New
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$134K -$942K -123,560 -84%
1
2
3 4

KPTI Hedge Fund Activity: Q1 2026 in Review

77 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2026, worth a combined $102M — up 47% from $69.6M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KPTI positions and 15 closed out — a net gain of 10 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Commodore Capital, opening a new position worth an estimated $14.9M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.84M sold.

  • 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2026, up from 69 in Q4 2025.
  • Funds reported $102M of Karyopharm Therapeutics stock for Q1 2026, up 47% quarter-over-quarter.
  • 25 funds opened new Karyopharm Therapeutics positions in Q1 2026 and 15 closed out, a net change of +10 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2026 was Commodore Capital, an estimated $14.9M added.
  • The largest Karyopharm Therapeutics seller in Q1 2026 was Opaleye Management, an estimated $6.84M sold.

Based on aggregated 13F filings for Q1 2026.